Advertisement EY mid banner
Barr Ellison Solicitors – commercial property
RealVNC mid-banner general
RealVNC mid banner careers
Advertisement: Mogrify
Mid banner advertisement: BDO
Advertisement: Cambridge Network
ARM Innovation Hub
Advertisement: EBCam mid banner
Advertisement: RSM
Advertisement: Simpsons Creative
Advertisement: China mid banner
16 April, 2019 - 12:48 By Kate Sweeney

Lonza engages with Stevenage Bioscience Catalyst

Dr Sally Ann Forsyth

Swiss multinational chemicals and biotech company Lonza –  a £4.2 billion powerhouse – is setting up a virtual tenancy at Stevenage Bioscience Catalyst. 

Through the collaboration, Lonza’s scientific experts will establish a regular presence at SBC working with the business development team, joining a vibrant community for biotech growth and development.

Headquartered in Basel, Lonza has major facilities in Europe, North America and South Asia. Founded in 1897 in the Swiss Alps, Lonza now has more than 100 sites and offices and approximately 15,500 full-time employees worldwide and generated sales of CHF 5.5 billion (£4.19bn) in 2018. 

Sarah Holland, global head of licensing at Lonza said: “Supporting innovation is a key focus for Lonza. Working closely with SBC gives us the opportunity to build strong relationships with other residents at the BioCatalyst. 

“Interacting with other companies in this highly networked and innovative environment, in one of the UK’s leading hotspots for life science innovation, will help fast-track opportunities for collaboration and set programs up early for industrial-quality manufacturing platforms.”

Dr Sally Ann Forsyth, CEO of SBC, added: “This is a great opportunity to create synergies between a large organisation such as Lonza and our entrepreneurial environment. 

“Our ultimate aim is to close the gap between translational innovative science and medical advancement; through this new initiative, we will be able to support further collaboration and accelerate that process.”

Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through its Pharma Biotech & Nutrition segment and specialty ingredients segment businesses, it harnesses science & technology to serve markets along this continuum. 

It focuses on promoting a healthier lifestyle and preventing illness through consumers’ preventive healthcare, as well as improving patient healthcare by supporting customers to deliver innovative medicines that help treat or cure severe diseases. 

Newsletter Subscription

Stay informed of the latest news and features